Climb Bio (CLYM) Assets Average (2021 - 2026)

Climb Bio has reported Assets Average for 6 years, with the latest figure at $160.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 23.4% year-over-year to $160.1 million; the trailing twelve-month figure through Mar 2026 stood at $160.1 million (down 23.4% YoY), and the FY2025 full-year result was $192.5 million, up 17.48% from the prior year.
• Assets Average for Q1 2026 stood at $160.1 million, down from $175.0 million in the prior quarter.
• The five-year high for Assets Average was $224.1 million in Q3 2024, with the low at $109.9 million in Q1 2024.
• Historically, Assets Average has averaged $160.6 million across 5 years, with a median of $160.1 million in 2026.
• Annual changes were most pronounced in 2023 — Assets Average dropped 23.73% — and 2024, when it jumped 96.85%.
• Climb Bio's Assets Average stood at $137.9 million in 2022, then slipped by 19.09% to $111.6 million in 2023, then jumped by 96.85% to $219.7 million in 2024, then slipped by 20.33% to $175.0 million in 2025, then declined by 8.55% to $160.1 million in 2026.
• The last three Assets Average figures came in at $160.1 million (Q1 2026), $175.0 million (Q4 2025), and $187.3 million (Q3 2025), per Business Quant data.